Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...
On Tuesday, the FDA approved NovoCure’s (NASDAQ:NVCR) Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel ...
Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...
Novocure GmbH secured U.S. FDA approval for Optune Lua, a wearable device that delivers alternating electric fields or tumor treating fields that kill cancer cells. Indicated for use with PD-1/PD-L1 ...
Jazz Pharmaceuticals announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca in combination ...
Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...
The US Food and Drug Administration (FDA) has approved Novocure's Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or ...
Larry Biegelsen, an analyst from Wells Fargo, maintained the Buy rating on NovoCure (NVCR – Research Report). The associated price target ...
Notably, 370 (83%) participants had squamous cell carcinoma, 215 (48%) had received previous chemoradiotherapy, 116 (26%) had a programmed cell death ligand 1 (PD-L1) combined positive score (CPS) of ...
A Prescription Drug User Fee Act target action date of June 13, 2025, has been set for the new drug application of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback